MoonLake Investors Urged to Seek Lead Role in SDNY Securities Case as Dec. 15 Deadline Nears
The case focuses on alleged misstatements about sonelokimab’s touted advantages following weak Phase 3 data that coincided with a steep share-price drop.
Overview
- A securities class action against MoonLake Immunotherapeutics is pending in the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, No. 1:25-cv-08612.
- The putative class covers purchasers from March 10, 2024 through September 29, 2025, and investors have until December 15, 2025 to move for lead-plaintiff appointment.
- Complaints allege MoonLake overstated sonelokimab’s Nanobody-derived superiority over monoclonal antibodies, citing comparisons to FDA-approved BIMZELX.
- On September 28, 2025, MoonLake reported Week-16 VELA Phase 3 results with VELA-2 missing its primary endpoint, a data set some analysts described as “disastrous.”
- MoonLake shares fell nearly 90% to $6.24 on September 29, 2025 after the disclosure, and multiple firms including Bleichmar Fonti & Auld, DJS Law Group, Schall, and Berger Montague are soliciting investors.